Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
63.949,86
1,69%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Agile Therapeutics Inc (AGRX) Agile Therapeutics Inc (AGRX) Notizie

AGRX

Agile Therapeutics (AGRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AGRX
DataOraFonteTitoloSimboloCompagnia
28/03/202413:05GlobeNewswire Inc.Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGRXAgile Therapeutics Inc
25/03/202421:30GlobeNewswire Inc.Agile Therapeutics Announces Delisting from NasdaqNASDAQ:AGRXAgile Therapeutics Inc
21/03/202411:35GlobeNewswire Inc.Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024NASDAQ:AGRXAgile Therapeutics Inc
20/03/202413:15GlobeNewswire Inc.Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024NASDAQ:AGRXAgile Therapeutics Inc
13/03/202412:31GlobeNewswire Inc.Agile Therapeutics Completes Pay-off of Debt and Remains Focused on Business Plan ExecutionNASDAQ:AGRXAgile Therapeutics Inc
23/02/202422:57Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AGRXAgile Therapeutics Inc
22/02/202415:01GlobeNewswire Inc.Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross ProceedsNASDAQ:AGRXAgile Therapeutics Inc
15/02/202422:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGRXAgile Therapeutics Inc
15/02/202422:30GlobeNewswire Inc.Agile Therapeutics Announces Extension Granted by Nasdaq Hearings Panel to Regain Compliance with the Stockholders’ Equity Continued Listing Requirement & Provides Performance UpdateNASDAQ:AGRXAgile Therapeutics Inc
14/02/202402:02Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGRXAgile Therapeutics Inc
07/02/202422:51Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:AGRXAgile Therapeutics Inc
23/01/202415:29GlobeNewswire Inc.The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without CostNASDAQ:AGRXAgile Therapeutics Inc
12/12/202314:01GlobeNewswire Inc.Agile Therapeutics Provides Update on Actions Being Taken to Strengthen the Affordable Care Act’s No-Cost Contraceptive Coverage RequirementNASDAQ:AGRXAgile Therapeutics Inc
11/12/202323:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:AGRXAgile Therapeutics Inc
09/11/202322:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGRXAgile Therapeutics Inc
09/11/202314:05GlobeNewswire Inc.Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGRXAgile Therapeutics Inc
26/10/202314:05GlobeNewswire Inc.Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023NASDAQ:AGRXAgile Therapeutics Inc
04/10/202322:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGRXAgile Therapeutics Inc
04/10/202322:30GlobeNewswire Inc.Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGRXAgile Therapeutics Inc
05/09/202314:05GlobeNewswire Inc.Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:AGRXAgile Therapeutics Inc
25/08/202322:02Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:AGRXAgile Therapeutics Inc
22/08/202314:30Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:AGRXAgile Therapeutics Inc
09/08/202314:05GlobeNewswire Inc.Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:AGRXAgile Therapeutics Inc
26/07/202314:30GlobeNewswire Inc.Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023NASDAQ:AGRXAgile Therapeutics Inc
27/06/202322:47Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AGRXAgile Therapeutics Inc
26/06/202314:01GlobeNewswire Inc.Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse MembersNASDAQ:AGRXAgile Therapeutics Inc
23/06/202318:05GlobeNewswire Inc.Agile Therapeutics Commends the Biden Administration’s Commitment to Strengthening Access to Affordable, High-Quality Contraception and Family Planning ServicesNASDAQ:AGRXAgile Therapeutics Inc
15/06/202322:05GlobeNewswire Inc.Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s HealthNASDAQ:AGRXAgile Therapeutics Inc
14/06/202322:36Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:AGRXAgile Therapeutics Inc
13/06/202322:05GlobeNewswire Inc.Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®NASDAQ:AGRXAgile Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:AGRX

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network